RankingsPricing
  1. US-listed companies
  2. NeuBase Therapeutics, Inc.
  3. Financials
  4. Common stock and paid-in capital

NeuBase Therapeutics, Inc.NBSE

Market cap
$1.41M
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Sep 30, 2022126+2.36%
Sep 30, 2021123+64.37%
Sep 30, 202075+106.76%
Sep 30, 201936+64648946.43%
Sep 30, 20180-100.00%
Sep 30, 2017131+19.86%
Sep 30, 2016109+8.16%
Sep 30, 2015101+44.15%
Sep 30, 201470+77.62%
Sep 30, 201339+27.38%
Sep 30, 201231+38.91%
Sep 30, 201122

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)